Predictors of immunotherapy benefit in Merkel cell carcinoma

SUPPLEMENTARY MATERIALS

Supplementary Table 1: Details of staging at diagnosis

	Number of patients
Stage IIIA	11
Stage IIIB	17
cN0	12
cN1	20
cN2	5
cN3	7
cNX	1
pN0	11
pN1	20
pN2	5
pN3	7
pNX	2

"c" indicates clinical staging, "p" indicates pathologic staging.

Supplementary Table 2: Radiographic best response to immune checkpoint inhibitor therapy

Best response	Total (n = 39)
	Number (%)
Complete response	13 (33)
Partial response	4 (10)
Stable disease	5 (13)
Progressive disease	17 (44)

Table includes the 39 patients with evaluable disease (underwent restaging scans following immune checkpoint inhibitor initiation).

Supplementary Table 3: Specific amino acid alterations at single nucleotide variant sites. See Supplementary Table 3